Barrett's esophagus (BE) is a premalignant condition for esophageal adenocarcinoma (EAC) which has dismal prognosis. The risk of progression from BE to EAC increases with dysplasia grade. The purpose of surveillance exams in BE is to detect dysplasia at an early stage and intervene before development of EAC. However, the current surveillance practices have not been effective in reducing EAC incidence. Major limitations of this strategy include challenges in identifying dysplasia during endoscopic surveillance, which leads to sampling error and subjectivity in the histological diagnosis of dysplasia due to interobserver variation amongst pathologists. Advanced imaging techniques may allow targeted biopsy of suspicious foci with incremental yield in dysplasia detection and reduce sampling error. Molecular biomarker panels have the potential to objectively assess progression risk without the subjectivity associated with histology. Combining molecular markers with advanced imaging appears to be a promising strategy to further improve risk stratification and reduce EAC incidence and mortality. Few studies have investigated this strategy so far and the results are promising. Further research on different permutations between the available biomarkers and imaging techniques will help us determine the best possible combination that detects dysplasia with high sensitivity and specificity. Further research is needed to establish the combined strategy's cost effectiveness and feasibility.
|Original language||English (US)|
|Number of pages||13|
|Journal||Best Practice and Research: Clinical Gastroenterology|
|State||Published - Aug 1 2015|
- Barrett's esophagus
- Esophageal adenocarcinoma
ASJC Scopus subject areas